QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Works matching IS 17762596 AND DT 2015 AND VI 10 AND IP 1
Results: 17
1
2
A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.
- Published in:
- 2015
- By:
- Publication type:
- journal article
3
Transforming growth factor-beta and its implication in the malignancy of gliomas.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 1, p. 1, doi. 10.1007/s11523-014-0308-y
- By:
- Publication type:
- Article
4
An observational cohort study of bevacizumab and chemotherapy in metastatic colorectal cancer patients: safety and efficacy with analysis by age group.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 1, p. 55, doi. 10.1007/s11523-014-0311-3
- By:
- Publication type:
- Article
5
Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 1, p. 65, doi. 10.1007/s11523-014-0315-z
- By:
- Publication type:
- Article
6
Study on mouse model of triple-negative breast cancer: association between higher parity and triple-negative breast cancer.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 1, p. 85, doi. 10.1007/s11523-014-0316-y
- By:
- Publication type:
- Article
7
Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 1, p. 77, doi. 10.1007/s11523-014-0318-9
- By:
- Publication type:
- Article
8
A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 1, p. 99, doi. 10.1007/s11523-014-0319-8
- By:
- Publication type:
- Article
9
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 1, p. 111, doi. 10.1007/s11523-014-0320-2
- By:
- Publication type:
- Article
10
Early skin toxicity predicts better outcomes, and early tumor shrinkage predicts better response after cetuximab treatment in advanced colorectal cancer.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 1, p. 125, doi. 10.1007/s11523-014-0322-0
- By:
- Publication type:
- Article
11
The status of radioimmunotherapy in CD20+ non-Hodgkin's lymphoma.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 1, p. 15, doi. 10.1007/s11523-014-0324-y
- By:
- Publication type:
- Article
12
QT prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 1, p. 27, doi. 10.1007/s11523-014-0325-x
- By:
- Publication type:
- Article
13
Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 1, p. 135, doi. 10.1007/s11523-014-0326-9
- By:
- Publication type:
- Article
14
Gefitinib: a review of its use in adults with advanced non-small cell lung cancer.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 1, p. 153, doi. 10.1007/s11523-015-0358-9
- By:
- Publication type:
- Article
15
Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin's lymphoma.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 1, p. 141, doi. 10.1007/s11523-015-0359-8
- By:
- Publication type:
- Article
16
Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 1, p. 171, doi. 10.1007/s11523-015-0363-z
- By:
- Publication type:
- Article
17
Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 1, p. 45, doi. 10.1007/s11523-014-0307-z
- By:
- Publication type:
- Article